2 completed, 1 active not recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Beth Christian: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma gemcitabine hydrochloride, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 26 | 2012-02-09 | 2021-11-19 |
| Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma milatuzumab, veltuzumab, Correlative/Special Studies - Lymphoma | Phase 1 / Phase 2 | Completed | Beth Christian | 35 | 2009-09-01 | 2017-02-06 |
Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Burkitt Lymphoma (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Antibodies, Monoclonal (1) · Bendamustine Hydrochloride (1) · Blood Specimen Collection (1) · Gemcitabine (1) · Lenalidomide (1) · Pharmacokinetics (1) · milatuzumab (1) · obinutuzumab (1) · veltuzumab (1) · venetoclax (1)
United States (3)